早期阿尔茨海默病查方法使用血生物标志物
Lourdes Álvarez-Sánchez1, Carmen Peña-Bautista1, Laura Ferré-González1
1Alzheimer Disease Research Group, Health Research Institute La Fe, 46026 Valencia, Spain.
International journal of molecular sciences
|September 28, 2023
概括
这项研究确定了用于早期阿尔茨海默病 (AD) 查的血生物标志物. 化陶 (p-Tau181) 和状纤维酸蛋白 (GFAP) 在区分AD与其他神经认知障碍方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 诊断工具 诊断工具
背景情况:
- 阿尔茨海默氏病 (AD) 是最常见的痴呆症,经常出现重叠的症状与其他神经认知障碍,如勒维体病 (LBD) 和前性痴呆症 (FTD).
- 准确和早期诊断对于AD的有效管理和治疗至关重要.
- 需要可靠的血生物标志物来区分AD与其他具有相似初始症状的疾病.
研究的目的:
- 评估血生物标志物,特别是p-Tau181,神经丝光 (NfL) 和质纤维酸蛋白 (GFAP),以开发早期和特定的AD查方法.
- 评估这些生物标志物的诊断准确性,以区分AD与其他神经认知障碍.
主要方法:
- 使用单分子测试 (SIMOA) 测量了p-Tau181,NfL和GFAP的血水平,这些患者因AD (MCI-AD),AD痴呆症,FTD,LBD和主观认知障碍 (SCI) 导致轻度认知障碍.
- 开发了一种部分最小方形 (PLS) 诊断模型,使用接收器操作特征 (ROC) 分析来评估诊断性能.
主要成果:
- 在AD痴呆症患者中,血p-Tau181和GFAP水平显著升高,与AD临床特征相关.
- 神经纤维光 (NfL) 水平在FTD患者中最高,与AD没有显著的相关性.
- 在区分AD和SCI方面,PLS模型表现出高准确度 (AUC0.935,86%的灵敏度,88%的特异性).
结论:
- 血NfL可以作为初步选,在认知障碍患者中识别FTD患者.
- 血p-Tau181和GFAP的组合,集成到一个PLS模型中,为AD提供了简单,早期和特定的诊断方法.
- 这些发现支持了血生物标志物的潜力,用于非侵入性和准确的AD诊断.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.4K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
相关概念视频
01:26Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212